SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-311141
Filing Date
2020-12-07
Accepted
2020-12-07 07:03:18
Documents
13
Period of Report
2020-12-03
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d85305d8k.htm   iXBRL 8-K 33565
2 EX-3.1 d85305dex31.htm EX-3.1 184038
  Complete submission text file 0001193125-20-311141.txt   386278

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20201203.xsd EX-101.SCH 3084
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20201203_lab.xml EX-101.LAB 18873
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20201203_pre.xml EX-101.PRE 11866
6 EXTRACTED XBRL INSTANCE DOCUMENT d85305d8k_htm.xml XML 3569
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 201371315
SIC: 2834 Pharmaceutical Preparations